Pfizer Inc.PFENYSE
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank54
3Y CAGR-28.1%
5Y CAGR-37.4%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-28.1%/yr
vs -14.5%/yr prior
5Y CAGR
-37.4%/yr
Recent acceleration
Acceleration
-13.6pp
Decelerating
Percentile
P54
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 16.21% |
| Q3 2025 | 890.89% |
| Q2 2025 | -124.93% |
| Q1 2025 | -65.26% |
| Q4 2024 | 0.10% |
| Q3 2024 | 476.98% |
| Q2 2024 | -263.39% |
| Q1 2024 | -79.20% |
| Q4 2023 | 51.62% |
| Q4 2023 | 385.86% |
| Q3 2023 | -199.67% |
| Q2 2023 | -85.87% |
| Q4 2022 | 43.66% |
| Q4 2022 | -26.87% |
| Q3 2022 | 24.89% |
| Q2 2022 | 10.60% |
| Q4 2021 | -45.39% |
| Q4 2021 | -4.16% |
| Q3 2021 | 148.99% |
| Q2 2021 | -19.32% |
| Q4 2020 | 169.14% |
| Q3 2020 | -41.21% |
| Q2 2020 | 13.47% |
| Q1 2020 | -16.87% |
| Q4 2019 | -16.43% |
| Q3 2019 | 72.73% |
| Q2 2019 | 53.77% |
| Q1 2019 | -64.16% |
| Q4 2018 | -9.91% |
| Q3 2018 | 36.70% |
| Q3 2018 | 94.00% |
| Q2 2018 | -70.59% |
| Q4 2017 | 37.96% |
| Q4 2017 | 50.28% |
| Q3 2017 | 104.66% |
| Q2 2017 | -73.39% |
| Q4 2016 | 27.09% |
| Q4 2016 | 31.29% |
| Q3 2016 | 116.78% |
| Q2 2016 | -64.97% |